A spinal implant designed to improve surgical outcomes in lumbar discectomy patients, Barricaid has been proven effective by closing the defects in the disc annulus that are larger than five millimeters in width. The United States Food and Drug Administration awarded the Barricaid premarket approval in February 2019.

At the 2018 Brussels International Spine Symposium, Prof. Richard Assaker reported a 25 percent re-herniation rate in patients that are left with large postoperative defects in the annulus. In light of these statistics, Prof. Mark Arts presented three-year results showing that Barricaid can cut chances of lumbar discectomy re-operation by half, and Dr. Scott Blumenthal gave the Barricaid a favorable health economic analysis.

The innovative medical device company Intrinsic Therapeutics manufactures Barricaid under the direction of Founder/Executive Director Gregory Lambrecht and Chief Executive Officer/President/Director Cary P. Hagan. The company is headquartered in the Boston suburb of Woburn, Massachusetts, and supports satellite offices in both Germany and the Netherlands.